NV-AMBARELLA
2.1.2020 11:02:12 CET | Business Wire | Press release
Ambarella, Inc. (Nasdaq: AMBA), an artificial intelligence (AI) vision silicon company, today announced that Ambarella and Amazon Web Services, Inc. (AWS) customers can now use Amazon SageMaker Neo to train machine learning (ML) models once and run them on any device equipped with an Ambarella CVflow®-powered AI vision system on chip (SoC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200102005052/en/
Until now, developers had to manually optimize ML models for devices based on Ambarella AI vision SoCs. This step could add considerable delays and errors to the application development process. Ambarella and AWS collaborated to simplify the process by integrating the Ambarella toolchain with the Amazon SageMaker Neo cloud service. Now, developers can simply bring their trained models to Amazon SageMaker Neo and automatically optimize the model for Ambarella CVflow-powered SoCs.
Customers can build an ML model using MXNet, TensorFlow, PyTorch, or XGBoost and train the model using Amazon SageMaker in the cloud or on their local machine. Then, they can upload the model to their AWS account and use Amazon SageMaker Neo to optimize the model for Ambarella SoCs. They can choose CV25, CV22, or CV2 as the compilation target. Amazon SageMaker Neo compiles the trained model into an executable that is optimized for Ambarella’s CVflow neural network accelerator. The compiler applies a series of optimizations that can make the model run up to 2x faster on the Ambarella SoC. Customers can download the compiled model and deploy it to their fleet of Ambarella-equipped devices. The optimized model runs in the Amazon SageMaker Neo runtime purpose-built for Ambarella SoCs and available for the Ambarella SDK. The Amazon SageMaker Neo runtime occupies less than 10x the disk and memory footprint of TensorFlow, MXNet, or PyTorch, making it much more efficient to deploy ML models on connected cameras.
“Ambarella is in mass production today with CVflow AI vision processors for the home monitoring, enterprise video security, and automotive markets,” said Chris Day, vice president of marketing and business development for Ambarella. “The ability to select an Ambarella SoC and compile a trained ML model with a single click is a powerful tool that makes it possible for our customers to rapidly bring the next generation of AI-enabled products to market.”
Manufactured using an advanced 10-nanometer process, Ambarella’s CVflow SoC family enables the design of compact, high-performance vision systems with ultra-low power operation. For example, the Ambarella CV22 CVflow SoC delivers computer vision processing at full 4K or 8-megapixel resolution at 30 frames per second (fps), while its image signal processor (ISP) provides outstanding imaging in low light conditions and high-contrast scenes, further enhancing the computer vision capabilities of the chip. The CV22 also includes a suite of advanced security features to protect against hacking including secure boot, TrustZone®, I/O virtualization, and support for online upgrades over the air (OTA).
“AWS has the broadest and deepest set of ML and AI services focused on solving some of the toughest challenges facing developers. Amazon SageMaker is a fully managed service that provides every developer and data scientist with the ability to build, train, and deploy machine learning models quickly,” said Bratin Saha, vice president, Machine Learning & Engines, Amazon Web Services, Inc. “We’re excited that VIVOTEK is using SageMaker Neo to simplify the deployment of ML models at the edge on Ambarella CVflow-powered IP cameras.”
VIVOTEK (TWSE:3454), a leading global IP surveillance solution provider and customer of both Ambarella and AWS, will now be able to deploy advanced ML capabilities to a new camera product line—powered by the Ambarella CV series SoCs—more quickly using Amazon SageMaker Neo. Dr. Steve Ma, vice president of engineering, Brand Business Division, VIVOTEK INC. said, “We’re excited that we will be able to explore training and deploying the machine learning models increasingly demanded by our customers to our future Ambarella CV series powered cameras with Amazon SageMaker Neo, potentially saving us months of hand-tuning the individual models for optimal performance on the edge. Using Amazon SageMaker Neo ensures that our IP camera solutions are fully able to leverage the market-leading computer vision capabilities of the Ambarella SoC.”
Ambarella will demonstrate the integration with Amazon SageMaker Neo during CES 2020 to select customers and partners.
The URL for this news release and the related image: https://www.ambarella.com/news-events/
About Ambarella
Ambarella’s products are used in a wide variety of human and computer vision applications, including video security, advanced driver assistance systems (ADAS), electronic mirror, drive recorder, driver/cabin monitoring, autonomous driving, and robotic applications. Ambarella’s low-power system on chips (SoCs) offer high-resolution video compression, advanced image processing, and powerful deep neural network processing to enable intelligent cameras to extract valuable data from high-resolution video streams. For more information, please visit www.ambarella.com
All brand names, product names, or trademarks belong to their respective holders. Ambarella reserves the right to alter product and service offerings, specifications and pricing at any time without notice. ©2020 Ambarella. All rights reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200102005052/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
